Related Experiment Video
Updated: Nov 11, 2025

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
Published on: July 12, 2021
Ketogenic Diet in Infants with Early-Onset Epileptic Encephalopathy and SCN2A Mutation
Xiaoyu Tian1, Yange Zhang1, Jinhong Zhang1
1Department of Pediatrics, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Insights
A ketogenic diet (KD) improved medically refractory seizures in an infant with a de novo SCN2A mutation causing early-onset epileptic encephalopathy (EOEE). This highlights KD feasibility in infants under two months for SCN2A-related EOEE.
Area of Science:
- Genetics
- Neurology
- Pediatrics
Background:
- Mutations in the SCN2A gene are linked to early-onset epileptic encephalopathies (EOEEs), causing developmental delays and infantile seizures.
- SCN2A mutations are a significant genetic cause of severe epilepsy in infants.
- Early-onset epileptic encephalopathies present a major challenge in pediatric neurology due to treatment resistance.
Abstract:
Research has shown mutations in the voltage-gated sodium channel gene SCN2A to be associated with developmental delays and infantile seizures in patients with early-onset epileptic encephalopathies (EOEEs). Here, we report the case of an infant with a de novo SCN2A mutation with EOEE who had medically refractory seizures that improved with a ketogenic diet (KD) implemented at an age less than 2 months. On the day of his birth, the infant presented with a pattern of convulsions with dozens of episodes per day. An initial video electroencephalogram revealed poor reactivity of background activity, with multiple partial episodes starting from the right temporal region, and abnormal electrical activity in the right hemisphere. The seizures previously were not controlled with successive therapy with phenobarbital, topiramate, and levetiracetam. Genetic testing revealed the presence of a mutation in the SCN2A gene (c.4425C>G, p.Asn1475Lys). The infant's seizures decreased significantly with a combination of KD and medication. The present case exemplifies the potential for personalized genomics in identifying the etiology of an illness. Furthermore, the KD appears to feasible in infants younger than 2 months and might elicit good responses to EOEE associated with SCN2A mutation.
More Related Videos
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
Related Concept Videos
Inborn Errors of Metabolism
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Glutamate Antagonists
Pharmacokinetics in Pediatric Patients: Drug Metabolism